How to implement incretin therapy

Journal of Family Practice

Volumn 57, Issue 9 SUPPL., 2008, Pages

  Cobble, Michael E ^a,b,c,d,e,f  

^a ABBOTT LABORATORIES   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c TheraSim Inc

^d ASTRAZENECA   (United Kingdom)

^e Forest Pharmaceuticals

^f GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALOGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; INCRETIN; LIRAGLUTIDE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ABSENCE OF SIDE EFFECTS; CLINICAL TRIAL; DIET RESTRICTION; DIET THERAPY; DRUG DOSE REDUCTION; DRUG SAFETY; EXERCISE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LIFESTYLE MODIFICATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATIENT EDUCATION; PATIENT SELECTION; REVIEW; SATIETY; SIDE EFFECT; STOMACH EMPTYING; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT EDUCATION AS TOPIC; PATIENT SELECTION;

EID: 51949099680     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care. 2008;31(suppl 1):S12-S54.
2. Rodbard HW, Blonde L, Braithwaite SS, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(suppl 1):3-68.
3. Nelson P, Poon T, Guan X, et al. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. Diabetes Technol Ther. 2007;9:317-326.
4. Zinman B, Hoogwerf BJ, Duran GS, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2007;146:477-485.
5. Vilsboll T, Zdravkovic M, Le Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007;30:1608-1610.
6. Nauck MA, Frid A, Hermansen K, et al. Liraglutide, a once-daily human GLP-1 analog, in type 2 diabetes provides similar glycemic control with reduced body weight compared with glimepiride when added to metformin. Presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.
7. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29:2632-2637.
8. Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28:1556-1568.
9. Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care. 2007;30:217-223.
10. Ahren B, Gomis R, Standi E, et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2874-2880.
11. Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther. 2008;30:499-512.
12. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab. 2008;10:376-386.
13. Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007;30:1487-1493.
14. Feinglos MN, Saad MF, Pi-Sunyer FX, et al. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes. Diabet Med. 2005;22:1016-1023.
15. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49:2564-2571.
16. Rosenstock J, Baron MA, Camisasca RP, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9:175-185.
17. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092-1100.
18. Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2007;50:259-267.
19. Madsbad S, Schmitz O, Ranstam J, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care. 2004;27:1335-1342.
20. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-2635.
21. Harder H, Nielsen L, Tu DT, et al. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care. 2004;27:1915-1921.
22. Gutzwiller JP, Drewe J, Goke B, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol. 1999;276:R1541-R1544.
23. Delgado-Aros S, Kim DY, Burton DD, et al. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol. 2002;282:G424-G431.
24. Gutzwiller JP, Goke B, Drewe J, et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut. 1999;44:81-86.
25. Mari A, Degn K, Brock B, et al. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. Diabetes Care. 2007;30:2032-2033.
26. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143:559-569.
27. Bolli G, Dotta F, Rochotte E, et al. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab. 2008;10:82-90.
28. Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007;50:1148-1155.
29. Scott R, Wu M, Sanchez M, et al. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract. 2007;61:171-180.
30. Pi-Sunyer FX, Schweizer A, Mills D, et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract. 2007;76:132-138.
31. Byetta [prescribing information]. San Diego, CA: Amylin Pharmaceuticals, Inc.; 2008.
32. HoIst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and non-diabetic humans. Am J Physiol Endocrinol Metab. 2004;287:E199-E206.
33. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298:194-206.
34. Garber A, Henry R, Ratner R, et al. Significantly better glycemic control and weight reduction with liraglutide, a once-daily human GLP-1 analog, compared with glimepiride: All as monotherapy in type 2 diabetes. Presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.
35. Colagiuri S, Frid A, Zdravkovic M, et al. The once-daily human GLP-1 analog liraglutide reduces systolic blood pressure in patients with type 2 diabetes. Presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.
36. Jendle J, Nauck MA, Matthews D, et al. Liraglutide, a once-daily human GLP-1 analog, reduces fat percentage, visceral and subcutaneous adipose tissue and hepatic steatosis compared with glimepiride when added to metformin in subjects with type 2 diabetes. Presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.
37. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analog, added to a sulfonylurea (SU) offers significantly better glycemic control and favorable weight change compared with rosiglitazone and SU combination therapy in subjects with type 2 diabetes. Presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.
38. Matthews D, Marre M, Le-Thi TD, et al. Liraglutide, a once-daily human GLP-1 analog, significantly improves beta-cell function in subjects with type 2 diabetes. Presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.
39. Nauck M, Brandle M, Vaag A, et al. The once-daily human GLP-1 analog liraglutide substantially reduces HbA1c in subjects with type 2 diabetes, irrespective of HbA1c at baseline. Presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.
40. Russell-Jones D, Vaag A, Schmitz O, et al. Significantly better glycemic control and weight reduction with liraglutide, a once-daily human GLP-1 analog, compared with insulin glargine: All as add-on to metformin and a sulfonylurea in type 2 diabetes. Presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.
41. Agerso H, Jensen LB, Elbrond B, et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002;45:195-202.
42. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004;53:1187-1194.
43. Januvia [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc.; 2007.
44. Novartis faces delay rolling out Galvus. http://www.fiercebiotech.com/ story/novartis-faces-delay-roll-ing-out-galvus/2007-11-06. Accessed June 25, 2008.
45. Sunkara G, Sabo R, Wang Y, et al. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. J Clin Pharmacol. 2007;47:1152-1158.
46. Sato K, Ozaki H, Salamon CM, et al. Lack of dermal toxicity with the highly selective dipeptidyl peptidase-4 inhibitor alogliptin in monkeys. Presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.
47. DeFronzo R, Fleck P, Wilson C, et al. Alogliptin monotherapy improves glycemic control in patients with type 2 diabetes. Presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.
48. Pratley R, Kipnes M, Fleck P, et al. Alogliptin add ed to sulfonylurea therapy in patients with type 2 diabetes reduces HbA1c without increasing hypoglycemia. Presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.
49. Nauck M, Ellis G, Fleck P, et al. Efficacy and safety of alogliptin added to metformin therapy in patients with type 2 diabetes. Presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.
50. Pratley R, Reusch J, Fleck P, et al. Efficacy and safety of alogliptin added to pioglitazone therapy in patients with type 2 diabetes. Presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco CA.
51. Himyama M, Matsuno K, Fujita T, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of the dipeptidyl peptidase-4 inhibitor alogliptin in Japanese healthy male subjects. Presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.
52. Karim A, Fleck P, Hetman L, et al. Single-dose pharmacokinetics of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment. Presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.
53. Rosenstock J, Aguilar-Salinas CA, Klein E, et al. Once-daily saxagliptin monotherapy improves glycemic control in drug-naive patients with type 2 diabetes. Presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.
54. Boulton DW, Goyal A, Li L, et al. The effects of age and gender on the single-dose pharmacokinetics and safely of saxagliptin in healthy subjects. Presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.
55. Patel C, Castaneda L, Frevert U, et al. Single-dose pharmacokinetics and safety of saxagliptin in subjects with hepatic impairment compared with healthy subjects. Presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.
56. Ahren B, Pacini G, Foley JE, et al. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care. 2005;28:1936-1940.
57. Schnabel CA, Wintle M, Kolterman O. Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes. Vasc Health Risk Manag. 2006;2:69-77.
58. Mafong DD, Henry RR. Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction. Curr Atheroscler Rep. 2008;10:55-60.